<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6609826</article-id><article-id pub-id-type="pmid">31066120</article-id><article-id pub-id-type="doi">10.1111/cas.14035</article-id><article-id pub-id-type="publisher-id">CAS14035</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Cell, Molecular, and Stem Cell Biology</subject></subj-group></subj-group></article-categories><title-group><article-title>MicroRNA&#x02010;143/Musashi&#x02010;2/<styled-content style="fixed-case">KRAS</styled-content> cascade contributes positively to carcinogenesis in human bladder cancer</article-title><alt-title alt-title-type="left-running-head">TSUJINO et al.</alt-title></title-group><contrib-group><contrib id="cas14035-cr-0001" contrib-type="author"><name><surname>Tsujino</surname><given-names>Takuya</given-names></name><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1559-1889</contrib-id><xref ref-type="aff" rid="cas14035-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="cas14035-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas14035-cr-0002" contrib-type="author"><name><surname>Sugito</surname><given-names>Nobuhiko</given-names></name><xref ref-type="aff" rid="cas14035-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas14035-cr-0003" contrib-type="author"><name><surname>Taniguchi</surname><given-names>Kohei</given-names></name><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0648-1370</contrib-id><xref ref-type="aff" rid="cas14035-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cas14035-cr-0004" contrib-type="author"><name><surname>Honda</surname><given-names>Ryo</given-names></name><xref ref-type="aff" rid="cas14035-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas14035-cr-0005" contrib-type="author"><name><surname>Komura</surname><given-names>Kazumasa</given-names></name><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4157-1929</contrib-id><xref ref-type="aff" rid="cas14035-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="cas14035-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cas14035-cr-0006" contrib-type="author"><name><surname>Yoshikawa</surname><given-names>Yuki</given-names></name><xref ref-type="aff" rid="cas14035-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas14035-cr-0007" contrib-type="author"><name><surname>Takai</surname><given-names>Tomoaki</given-names></name><xref ref-type="aff" rid="cas14035-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas14035-cr-0008" contrib-type="author"><name><surname>Minami</surname><given-names>Koichiro</given-names></name><xref ref-type="aff" rid="cas14035-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas14035-cr-0009" contrib-type="author"><name><surname>Kuranaga</surname><given-names>Yuki</given-names></name><xref ref-type="aff" rid="cas14035-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas14035-cr-0010" contrib-type="author"><name><surname>Shinohara</surname><given-names>Haruka</given-names></name><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8326-1203</contrib-id><xref ref-type="aff" rid="cas14035-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas14035-cr-0011" contrib-type="author"><name><surname>Tokumaru</surname><given-names>Yoshihisa</given-names></name><xref ref-type="aff" rid="cas14035-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="cas14035-cr-0012" contrib-type="author"><name><surname>Heishima</surname><given-names>Kazuki</given-names></name><xref ref-type="aff" rid="cas14035-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas14035-cr-0013" contrib-type="author"><name><surname>Inamoto</surname><given-names>Teruo</given-names></name><xref ref-type="aff" rid="cas14035-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas14035-cr-0014" contrib-type="author"><name><surname>Azuma</surname><given-names>Haruhito</given-names></name><xref ref-type="aff" rid="cas14035-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas14035-cr-0015" contrib-type="author" corresp="yes"><name><surname>Akao</surname><given-names>Yukihiro</given-names></name><address><email>yakao@gifu-u.ac.jp</email></address><xref ref-type="aff" rid="cas14035-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="cas14035-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">United Graduate School of Drug Discovery and Medical Information Sciences</named-content>
<institution>Gifu University</institution>
<named-content content-type="city">Gifu</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas14035-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Urology</named-content>
<institution>Osaka Medical College</institution>
<named-content content-type="country-part">Osaka</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas14035-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Translational Research Program</named-content>
<institution>Osaka Medical College</institution>
<named-content content-type="country-part">Osaka</named-content>
<country country="JP">Japan</country>
</aff><aff id="cas14035-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Surgical Oncology</named-content>
<named-content content-type="organisation-division">Graduate School of Medicine</named-content>
<institution>Gifu University</institution>
<named-content content-type="city">Gifu</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Yukihiro Akao, United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu, Japan.<break/>
Email: <email>yakao@gifu-u.ac.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2019</year></pub-date><volume>110</volume><issue>7</issue><issue-id pub-id-type="doi">10.1111/cas.2019.110.issue-7</issue-id><fpage>2189</fpage><lpage>2199</lpage><history><date date-type="received"><day>21</day><month>11</month><year>2018</year></date><date date-type="rev-recd"><day>10</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2019</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 Japanese Cancer Association <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2019 The Authors. <italic>Cancer Science</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japanese Cancer Association.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-110-2189.pdf"/><abstract id="cas14035-abs-0001"><title>Abstract</title><p>It has been well established that micro<styled-content style="fixed-case">RNA</styled-content> (miR)&#x02010;143 is downregulated in human bladder cancer (<styled-content style="fixed-case">BC</styled-content>). Recent precision medicine has shown that mutations in <styled-content style="fixed-case">BC</styled-content> are frequently observed in <italic><styled-content style="fixed-case">FGFR</styled-content>3, <styled-content style="fixed-case">RAS</styled-content></italic> and <italic><styled-content style="fixed-case">PIK</styled-content>3<styled-content style="fixed-case">CA</styled-content></italic> genes, all of which correlate with <styled-content style="fixed-case">RAS</styled-content> signaling networks. We have previously shown that miR&#x02010;143 suppresses cell growth by inhibiting <styled-content style="fixed-case">RAS</styled-content> signaling networks in several cancers including <styled-content style="fixed-case">BC</styled-content>. In the present study, we showed that synthetic miR&#x02010;143 negatively regulated the <styled-content style="fixed-case">RNA</styled-content>&#x02010;binding protein Musashi&#x02010;2 (<styled-content style="fixed-case">MSI</styled-content>2) in <styled-content style="fixed-case">BC</styled-content> cell lines. <styled-content style="fixed-case">MSI</styled-content>2 is an <styled-content style="fixed-case">RNA</styled-content>&#x02010;binding protein that regulates the stability of certain <styled-content style="fixed-case">mRNA</styled-content>s and their translation by binding to the target sequences of the <styled-content style="fixed-case">mRNA</styled-content>s. Of note, the present study clarified that <styled-content style="fixed-case">MSI</styled-content>2 positively regulated <styled-content style="fixed-case">KRAS</styled-content> expression through directly binding to the target sequence of <italic><styled-content style="fixed-case">KRAS</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content> and promoting its translation, thus contributing to the maintenance of <styled-content style="fixed-case">KRAS</styled-content> expression. Thus, miR&#x02010;143 silenced <styled-content style="fixed-case">KRAS</styled-content> and <styled-content style="fixed-case">MSI</styled-content>2, which further downregulated <styled-content style="fixed-case">KRAS</styled-content> expression through perturbation of the <styled-content style="fixed-case">MSI</styled-content>2/<styled-content style="fixed-case">KRAS</styled-content> cascade.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cas14035-kwd-0001">bladder cancer</kwd><kwd id="cas14035-kwd-0002">KRAS</kwd><kwd id="cas14035-kwd-0003">miR&#x02010;143</kwd><kwd id="cas14035-kwd-0004">Musashi&#x02010;2</kwd><kwd id="cas14035-kwd-0005"><styled-content style="fixed-case">RNA</styled-content>&#x02010;binding protein</kwd></kwd-group><funding-group><award-group><funding-source>Japan Agency for Medical Research and Development</funding-source><award-id>16cm0106202&#x000a0;h0001</award-id></award-group></funding-group><counts><fig-count count="8"/><table-count count="0"/><page-count count="11"/><word-count count="6299"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>cas14035</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.5 mode:remove_FC converted:10.07.2019</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cas14035-cit-1001">
<string-name>
<surname>Tsujino</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sugito</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Taniguchi</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>MicroRNA&#x02010;143/Musashi&#x02010;2/KRAS cascade contributes positively to carcinogenesis in human bladder cancer</article-title>. <source xml:lang="en">Cancer Sci</source>. <year>2019</year>;<volume>110</volume>:<fpage>2189</fpage>&#x02013;<lpage>2199</lpage>. <pub-id pub-id-type="doi">10.1111/cas.14035</pub-id>
<pub-id pub-id-type="pmid">31066120</pub-id></mixed-citation>
</p></notes></front><body><sec id="cas14035-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Bladder cancer (BC) is the most common malignancy of the urinary tract. According to the American Cancer Society, approximately 79&#x000a0;000 new cases of BC and over 18&#x000a0;000 deaths were estimated to have occurred in the USA alone in 2017.<xref rid="cas14035-bib-0001" ref-type="ref">1</xref> Recent precision medicine showed that gene alternations in BC were frequently observed in <italic>FGFR3</italic>,<italic> RAS</italic> and <italic>PIK3CA</italic>,<xref rid="cas14035-bib-0002" ref-type="ref">2</xref>, <xref rid="cas14035-bib-0003" ref-type="ref">3</xref> all of which are correlated with RAS signaling networks. Among these networks, that of KRAS, in particular, is extremely complicated. Moreover, KRAS regulates more than 10 effector signaling pathways, and its expression is promoted mainly by receptor tyrosine kinases (RTK), including <italic>FGFR3</italic>.<xref rid="cas14035-bib-0004" ref-type="ref">4</xref>, <xref rid="cas14035-bib-0005" ref-type="ref">5</xref> Previous studies reported on the networks of KRAS.<xref rid="cas14035-bib-0006" ref-type="ref">6</xref>, <xref rid="cas14035-bib-0007" ref-type="ref">7</xref> In addition, microRNAs (miR) that directly target <italic>KRAS</italic> signaling impede KRAS&#x02010;driven tumorigenesis.<xref rid="cas14035-bib-0007" ref-type="ref">7</xref> Previous studies including ours demonstrated that miR&#x02010;143 suppresses KRAS&#x02010;mediated tumorigenesis.<xref rid="cas14035-bib-0008" ref-type="ref">8</xref>, <xref rid="cas14035-bib-0009" ref-type="ref">9</xref>, <xref rid="cas14035-bib-0010" ref-type="ref">10</xref> Moreover, miR&#x02010;143 is strongly downregulated in several cancers,<xref rid="cas14035-bib-0009" ref-type="ref">9</xref>, <xref rid="cas14035-bib-0011" ref-type="ref">11</xref>, <xref rid="cas14035-bib-0012" ref-type="ref">12</xref>, <xref rid="cas14035-bib-0013" ref-type="ref">13</xref>, <xref rid="cas14035-bib-0014" ref-type="ref">14</xref> including BC;<xref rid="cas14035-bib-0015" ref-type="ref">15</xref>, <xref rid="cas14035-bib-0016" ref-type="ref">16</xref> and it inhibits cell proliferation by suppressing both signaling pathways of PI3K/AKT and MAPK, which are downstream of KRAS effector signaling pathways, as well as KRAS in BC.<xref rid="cas14035-bib-0017" ref-type="ref">17</xref>
</p><p>The Musashi gene is a consequence of earlier gene duplication, and humans have two related genes, Musashi&#x02010;1 (<italic>MSI1</italic>) and Musashi&#x02010;2 (<italic>MSI2</italic>). MSI1 and MSI2 share approximately 75% amino acid identity in their overall structure and belong to a family of RNA&#x02010;binding proteins.<xref rid="cas14035-bib-0018" ref-type="ref">18</xref> MSI2 post&#x02010;transcriptionally regulates mRNA processing by binding to the recognition motifs located at the 3&#x02032;UTR of target mRNAs, similar to MSI1. MSI2 preferentially interacts with an ACCUUUUUAGAA motif and other poly&#x02010;U sequences,<xref rid="cas14035-bib-0019" ref-type="ref">19</xref> UAG motifs, and UAG&#x02010;containing motifs&#x000a0;&#x000b1;&#x000a0;additional flanking nucleotides.<xref rid="cas14035-bib-0020" ref-type="ref">20</xref>, <xref rid="cas14035-bib-0021" ref-type="ref">21</xref> The Musashi proteins were first linked to cancer based on studies showing elevated expression of MSI1 in gliomas,<xref rid="cas14035-bib-0022" ref-type="ref">22</xref> medulloblastomas,<xref rid="cas14035-bib-0023" ref-type="ref">23</xref> and hepatomas.<xref rid="cas14035-bib-0024" ref-type="ref">24</xref> MSI2 was identified as part of a translocation event with HoxA9 in chronic myeloid leukemias that preserved MSI2 RNA&#x02010;binding motifs,<xref rid="cas14035-bib-0025" ref-type="ref">25</xref> also implicating MSI2 in cancer development. The past several years have been marked by a surge of reports elucidating the frequency and mechanisms of involvement of MSI2, in particular, in multiple forms of human cancer,<xref rid="cas14035-bib-0019" ref-type="ref">19</xref>, <xref rid="cas14035-bib-0026" ref-type="ref">26</xref>, <xref rid="cas14035-bib-0027" ref-type="ref">27</xref>, <xref rid="cas14035-bib-0028" ref-type="ref">28</xref> including BC.<xref rid="cas14035-bib-0029" ref-type="ref">29</xref> Like MSI1, moreover, Dong et&#x000a0;al<xref rid="cas14035-bib-0030" ref-type="ref">30</xref> reported that MSI2 is directly regulated in a negative way by miR&#x02010;143.</p><p>In the present study, we clarified the correlation between <italic>KRAS</italic> and <italic>MSI2</italic>, both of which are targets of miR&#x02010;143. Notably, knockdown of <italic>MSI2</italic> induced downregulation of KRAS, and overexpression of <italic>MSI2</italic> upregulated KRAS without causing an increase in the level of <italic>KRAS</italic> mRNA. These results indicated that MSI2 post&#x02010;transcriptionally regulated KRAS expression. Furthermore, by using a luciferase reporter assay and surface plasmon resonance (SPR), we demonstrated that MSI2 positively regulated KRAS expression through directly binding to the target sequence UAGUA in the 3&#x02032;UTR region of <italic>KRAS</italic> mRNA. Taken together, our findings indicated the extremely potent anticancer activity of synthetic miR&#x02010;143 (syn&#x02010;miR&#x02010;143), and it enabled us to clarify and better understand the role of the novel miR&#x02010;143/MSI2/KRAS cascade in human BC.</p></sec><sec sec-type="materials-and-methods" id="cas14035-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><sec id="cas14035-sec-0003"><label>2.1</label><title>RNA immunoprecipitation</title><p>RNA immunoprecipitation (RIP) was carried out with a RIP&#x02010;assay Kit (Medical &#x00026; Biological Laboratories Co., Ltd., Aichi, Japan) according to the manufacturer's instructions.</p></sec><sec id="cas14035-sec-0004"><label>2.2</label><title>RNA&#x02010;stability measurements</title><p>The RNA polymerase II transcriptional inhibitor 5,6&#x02010;dichlorobenzimidazole riboside (DRB) was procured from Tokyo Chemical Industry (Tokyo, Japan). T24 cells were seeded on the day prior to transfection with the cDNA plasmid encoding <italic>MSI2</italic> or control vector. The cells were treated with DRB at 24&#x000a0;hours after transfection. Cellular RNA was harvested at time 0, 2, 4, 6 and 8&#x000a0;hours and used for qRT&#x02010;PCR analysis of <italic>KRAS</italic> mRNA. RNA half&#x02010;lives were calculated from linear regression of log&#x02010;transformed expression values.<xref rid="cas14035-bib-0031" ref-type="ref">31</xref> ANCOVA was carried out on the resulting regression lines to assess statistical significance.</p></sec><sec id="cas14035-sec-0005"><label>2.3</label><title>Human tumor xenograft model</title><p>Animal experimental protocols were approved by the Committee for Animal Research and Welfare of Gifu University (approval no. H30&#x02010;42). BALB/cSLC&#x02010;nu/nu (nude) mice were obtained from Japan SLC (Shizuoka, Japan). Human bladder cancer T24 cells were inoculated into the back of each mouse. At 7&#x000a0;days after the inoculation, we confirmed engraftment of the tumors. When the tumor size had reached approximately 100&#x000a0;mm<sup>3</sup>, treatment was started. siRNA or miRNA carried by Lipofectamine RNAi MAX ( Invitrogen, Carlsbad, CA, USA) was injected into the tumor every 2&#x000a0;days for a total of three times. Each group contained three mice. Tumor volume was calculated by the formula: 0.5236&#x000a0;L1 (L2)<sup>2</sup>, where L1 is the long axis and L2 is the short axis.</p><p>Other methods are shown in Data&#x000a0;<xref rid="cas14035-sup-0010" ref-type="supplementary-material">S1</xref>.</p></sec></sec><sec sec-type="results" id="cas14035-sec-0006"><label>3</label><title>RESULTS</title><sec id="cas14035-sec-0007"><label>3.1</label><title>Impact of KRAS on proliferation of bladder cancer cell lines</title><p>To investigate the function of KRAS as an oncogene in human BC, we first assessed the association between cell growth and KRAS and that between it and HRAS in BC cell lines T24 and 253JB&#x02010;V. Knockdown of <italic>HRAS</italic> by use of siRNA significantly suppressed cell proliferation, and knockdown of <italic>KRAS</italic> resulted in a more potent growth inhibition than that obtained with knockdown of <italic>HRAS</italic> (Figure&#x000a0;<xref rid="cas14035-fig-0001" ref-type="fig">1</xref>A). In addition, KRAS effector signaling proteins, AKT and ERK1/2, were downregulated by both knockdowns (Figure&#x000a0;<xref rid="cas14035-fig-0001" ref-type="fig">1</xref>B). Of note, this knockdown was more prominent in T24 cells, which have an <italic>HRAS</italic> mutation, not a <italic>KRAS</italic> one. These results suggested that KRAS contributed considerably to cell proliferation in BC, as did HRAS.</p><fig fig-type="Figure" xml:lang="en" id="cas14035-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>
<styled-content style="fixed-case">KRAS</styled-content> strongly contributes to cell growth in bladder cancer (<styled-content style="fixed-case">BC</styled-content>) cell lines. Cell growth inhibition (A) and protein expression (B) with siR&#x02010;<styled-content style="fixed-case">KRAS</styled-content> or siR&#x02010;<styled-content style="fixed-case">HRAS</styled-content> in T24 and 253<styled-content style="fixed-case">JB</styled-content>&#x02010;V cells. *<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>.05; **<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>.01. Means&#x000a0;+&#x000a0;<styled-content style="fixed-case">SD</styled-content> indicated by error bars are shown</p></caption><graphic id="nlm-graphic-3" xlink:href="CAS-110-2189-g001"/></fig></sec><sec id="cas14035-sec-0008"><label>3.2</label><title>Syn&#x02010;miR&#x02010;143 directly silences the key genes of KRAS networks and MSI2</title><p>Previously, we reported that miR&#x02010;143 inhibited cell proliferation with apoptosis through silencing PI3K/AKT and MAPK signaling pathways, which are major growth&#x02010;related effector signal pathways in <italic>KRAS</italic> networks in BC.<xref rid="cas14035-bib-0017" ref-type="ref">17</xref>, <xref rid="cas14035-bib-0032" ref-type="ref">32</xref> As shown in Figure&#x000a0;<xref rid="cas14035-fig-0002" ref-type="fig">2</xref>A, the expression levels of miR&#x02010;143 were extremely downregulated in both T24 and 253JB&#x02010;V cells. Recently, we developed a chemically modified miR&#x02010;143 that has potent RNase&#x02010;resistant anticancer activity (Figure&#x000a0;<xref rid="cas14035-sup-0001" ref-type="supplementary-material">S1</xref>). This syn&#x02010;miR&#x02010;143 silences not only KRAS but also KRAS effector signaling molecules, AKT and ERK.<xref rid="cas14035-bib-0010" ref-type="ref">10</xref>
</p><fig fig-type="Figure" xml:lang="en" id="cas14035-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Ectopic expression of microRNA (miR)&#x02010;143 induces significant downregulation of <styled-content style="fixed-case">KRAS</styled-content> and Musahi&#x02010;2 (<styled-content style="fixed-case">MSI</styled-content>2) through <styled-content style="fixed-case">RNA</styled-content> interference. A, Relative expression levels of miR&#x02010;143 in T24 and 253<styled-content style="fixed-case">JB</styled-content>&#x02010;V cells. B, Dose&#x02010;dependent effect of miR&#x02010;143 on cell viability and protein expression levels of the target genes. C, Above effects of miR&#x02010;143 were verified in cells treated with antagomiR&#x02010;143. D, Luciferase activities after cotransfection with control or miR&#x02010;143 and wild&#x02010;type or mutant&#x02010;type <styled-content style="fixed-case">pMIR</styled-content> vectors having the predictive miR&#x02010;143 binding site in the 3&#x02032;<styled-content style="fixed-case">UTR</styled-content> of <italic><styled-content style="fixed-case">MSI</styled-content>2</italic>. Left panel shows complementation in the regions of the 3&#x02032;<styled-content style="fixed-case">UTR</styled-content> of <italic><styled-content style="fixed-case">MSI</styled-content>2 </italic>
<styled-content style="fixed-case">mRNA</styled-content> (positions 173&#x02010;179: #1 and 180&#x02010;187: #2) to the mature miR&#x02010;143. Colored (red and green) sequences of two sites indicate the predicted binding sites for miR&#x02010;143. The nucleotide sequence of the mutated site is shown in blue. **<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>.01. Means&#x000a0;+&#x000a0;<styled-content style="fixed-case">SD</styled-content> indicated by error bars are shown. NS, not significant</p></caption><graphic id="nlm-graphic-5" xlink:href="CAS-110-2189-g002"/></fig><p>To clarify how KRAS networks contribute to carcinogenesis and cell growth in BC, we introduced syn&#x02010;miR&#x02010;143 into T24 cells, which induced apoptosis to a greater extent than that obtained with Ambion miR&#x02010;143 (Ambion, Carlsbad, CA, USA), probably as a result of extreme silencing of KRAS networks (Figure&#x000a0;<xref rid="cas14035-sup-0002" ref-type="supplementary-material">S2</xref>).<xref rid="cas14035-bib-0010" ref-type="ref">10</xref> As shown in Figure&#x000a0;<xref rid="cas14035-fig-0002" ref-type="fig">2</xref>B, ectopic expression of syn&#x02010;miR&#x02010;143 led to significant growth inhibition in both cell lines. Western blot analysis indicated that syn&#x02010;miR&#x02010;143 strongly decreased the expression of KRAS protein and its effector signaling proteins AKT and ERK1/2. Interestingly, RNA&#x02010;binding protein MSI2 was also downregulated. MSI2 was recently reported as a target of miR&#x02010;143 in cervical cancer<xref rid="cas14035-bib-0030" ref-type="ref">30</xref> and has the fourth&#x02010;most frequent genetic alterations in BC across almost all major cancers as assessed in The Cancer Genome Atlas (TCGA) BC cohort using the cBioPortal for Cancer Genomics (cBioPortal; Figure&#x000a0;<xref rid="cas14035-sup-0003" ref-type="supplementary-material">S3</xref>), and has specific target sequences recognized by miR&#x02010;143 according to in&#x000a0;silico prediction tools in TargetScan. In addition, treatment with antagomiR&#x02010;143 reversed the growth inhibition and lowered protein levels of both KRAS and MSI2 elicited by syn&#x02010;miR&#x02010;143 (Figure&#x000a0;<xref rid="cas14035-fig-0002" ref-type="fig">2</xref>C). To examine whether miR&#x02010;143 directly bound to the 3&#x02032;UTR region of <italic>MSI2</italic> mRNA, we cloned the 3&#x02032;UTR of <italic>MSI2</italic> mRNA containing the possible miR&#x02010;143 binding site in a reporter plasmid. As a result, luciferase activity of wild&#x02010;type pMIR&#x02010;MSI2 was inhibited after cotransfection with miR&#x02010;143 and the reporter plasmid DNA in T24 cells (Figure&#x000a0;<xref rid="cas14035-fig-0002" ref-type="fig">2</xref>D). In contrast, decrease in luciferase activity was abrogated in the case of mutated binding sites. Together, these results indicated that miR&#x02010;143 could silence MSI2 expression at the translation step and inhibit BC cell proliferation, in part, through suppression of MSI2 expression. Hence, next we focused on the oncogenic function of MSI2 and the interaction between MSI2 and KRAS.</p></sec><sec id="cas14035-sec-0009"><label>3.3</label><title>Musashi&#x02010;2 is upregulated in clinical tumor samples of BC</title><p>We examined the expression of MSI2 in 10 samples from BC patients by western blot analysis. Clinicopathological findings of the patients are shown in Table&#x000a0;<xref rid="cas14035-sup-009" ref-type="supplementary-material">S1</xref>. As shown in Figure&#x000a0;<xref rid="cas14035-fig-0003" ref-type="fig">3</xref>A, MSI2 was upregulated in six of the 10 clinical BC samples examined compared with its level in normal bladder tissues in the same patients, and expression of miR&#x02010;143 was downregulated in all cases according to qRT&#x02010;PCR results (Figure&#x000a0;<xref rid="cas14035-fig-0003" ref-type="fig">3</xref>B). Therefore, all cases of MSI2 overexpression corresponded to downregulation of miR&#x02010;143. In addition, qRT&#x02010;PCR analysis of <italic>MSI2</italic> mRNA showed upregulation in T24 and 253JB&#x02010;V cells, and the increase was more prominent in T24 cells than in 253JB&#x02010;V cells (Figure&#x000a0;<xref rid="cas14035-fig-0003" ref-type="fig">3</xref>C). Based on these results, we focused on T24 cells in the following experiments.</p><fig fig-type="Figure" xml:lang="en" id="cas14035-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Expression of Musahi&#x02010;2 (<styled-content style="fixed-case">MSI</styled-content>2) in clinical bladder cancer (<styled-content style="fixed-case">BC</styled-content>) samples and cell lines. A, Protein expression levels of <styled-content style="fixed-case">MSI</styled-content>2 in 10 <styled-content style="fixed-case">BC</styled-content> tumor tissue samples from <styled-content style="fixed-case">BC</styled-content> patients. Overexpression of <styled-content style="fixed-case">MSI</styled-content>2 in tumor samples is highlighted by red&#x02010;colored boxes. N, normal; T, tumor in the same patient. B, Relative expression levels of <styled-content style="fixed-case">MSI</styled-content>2 in T24 and 253<styled-content style="fixed-case">JB</styled-content>&#x02010;V cells. C, Relative <styled-content style="fixed-case">mRNA</styled-content> expression level of <italic><styled-content style="fixed-case">MSI</styled-content>2</italic> in <styled-content style="fixed-case">BC</styled-content> cell lines compared with that in <styled-content style="fixed-case">HUC</styled-content>. **<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>.01. Means&#x000a0;+&#x000a0;<styled-content style="fixed-case">SD</styled-content> indicated by error bars are shown. HUC, human urothelial cell; miR, microRNA</p></caption><graphic id="nlm-graphic-7" xlink:href="CAS-110-2189-g003"/></fig></sec><sec id="cas14035-sec-0010"><label>3.4</label><title>Relationship between MSI2 and KRAS or HRAS in T24 cells</title><p>To examine the interaction between MSI2 and KRAS, we carried out knockdown and overexpression of <italic>MSI2</italic> by using siRNA (Figure&#x000a0;<xref rid="cas14035-sup-0004" ref-type="supplementary-material">S4</xref>) and MSI2 expression vector (pF5A&#x02010;MSI2), respectively. Knockdown of <italic>MSI2</italic> by siR&#x02010;MSI2 induced cell growth inhibition along with downregulation of KRAS (Figure&#x000a0;<xref rid="cas14035-fig-0004" ref-type="fig">4</xref>A). In contrast, overexpression of <italic>MSI2</italic> promoted cell proliferation and upregulated KRAS (Figure&#x000a0;<xref rid="cas14035-fig-0004" ref-type="fig">4</xref>B). Importantly, no significant change in <italic>KRAS</italic> mRNA levels was observed in the case of either silencing or overexpression of MSI2 (Figure&#x000a0;<xref rid="cas14035-fig-0004" ref-type="fig">4</xref>A,B). On the contrary, expression levels of <italic>HRAS</italic> mRNA corresponded to those of MSI2. Taken together, these data suggested that KRAS and HRAS were downstream of MSI2 and that MSI2 may have post&#x02010;transcriptionally regulated the transcripts of <italic>KRAS</italic> and <italic>HRAS</italic>. Notably, the expression of MSI2 was also affected by KRAS or HRAS, because either knockdown of <italic>KRAS</italic> or <italic>HRAS</italic> caused a decrease in the expression of MSI2 protein (Figure&#x000a0;<xref rid="cas14035-fig-0004" ref-type="fig">4</xref>C). Also, silencing of either KRAS or HRAS caused the expression of HRAS or KRAS, respectively, to decrease. These results indicated that MSI2 and KRAS or HRAS are coordinated with each other, although it is difficult to clarify how MSI2 interacts with KRAS and HRAS, given the complicated nature of RAS signaling networks.</p><fig fig-type="Figure" xml:lang="en" id="cas14035-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Relationship between Musahi&#x02010;2 (<styled-content style="fixed-case">MSI</styled-content>2) and <styled-content style="fixed-case">KRAS</styled-content> or <styled-content style="fixed-case">HRAS</styled-content> in expression profiles of T24 cells. A, Effects of <italic><styled-content style="fixed-case">MSI</styled-content>2</italic> knockdown using si<styled-content style="fixed-case">RNA</styled-content> on cell growth (left panel). Protein and <styled-content style="fixed-case">mRNA</styled-content> expression levels of <italic><styled-content style="fixed-case">KRAS</styled-content></italic> and <italic><styled-content style="fixed-case">HRAS</styled-content></italic> after siR&#x02010;<styled-content style="fixed-case">MSI</styled-content>2 transfection (middle and right panels). B, Effects of <italic><styled-content style="fixed-case">MSI</styled-content>2</italic> knockdown and overexpression on cell growth (left panel). Protein and <styled-content style="fixed-case">mRNA</styled-content> expression levels of <italic><styled-content style="fixed-case">KRAS</styled-content></italic> and <italic><styled-content style="fixed-case">HRAS</styled-content></italic> in <styled-content style="fixed-case">MSI</styled-content>2&#x02010;silenced and &#x02010;overexpressed cells (middle and right panels). C, <styled-content style="fixed-case">MSI</styled-content>2 and <styled-content style="fixed-case">RAS</styled-content> protein profiles after transfection with siR&#x02010;<styled-content style="fixed-case">KRAS</styled-content> or siR&#x02010;<styled-content style="fixed-case">HRAS</styled-content>. *<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>.05; **<italic>P&#x000a0;</italic>&#x0003c;0.01. Means&#x000a0;+&#x000a0;<styled-content style="fixed-case">SD</styled-content> indicated by error bars are shown. NS, not significant</p></caption><graphic id="nlm-graphic-9" xlink:href="CAS-110-2189-g004"/></fig></sec><sec id="cas14035-sec-0011"><label>3.5</label><title>Musashi&#x02010;2 directly binds to mRNA of KRAS</title><p>To clarify whether or not MSI2 bound directly to mRNAs of <italic>KRAS</italic> and <italic>HRAS</italic>, using BC cells, we first carried out MSI2&#x02010;immunoprecipitation (IP) followed by qRT&#x02010;PCR. Western blot analysis, carried out as a quality check, showed that MSI2 was detected in input and MSI2&#x02010;IP samples only, not in the control IgG&#x02010;IP sample. qRT&#x02010;PCR findings showed that the MSI2&#x02010;immunoprecipitated RNA fraction was significantly enriched in <italic>KRAS</italic> mRNA (Figure&#x000a0;<xref rid="cas14035-fig-0005" ref-type="fig">5</xref>A), whereas there was no enrichment of <italic>HRAS</italic> mRNA in IgG or MSI2 fractions. These data suggested that MSI2 directly bound to <italic>KRAS</italic> but not to <italic>HRAS</italic>. Therefore, the data on HRAS observed in Figure&#x000a0;<xref rid="cas14035-fig-0004" ref-type="fig">4</xref>A,B were supposedly as a result of an indirect impact of MSI2.</p><fig fig-type="Figure" xml:lang="en" id="cas14035-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Musashi&#x02010;2 (<styled-content style="fixed-case">MSI</styled-content>2) directly binds to <styled-content style="fixed-case">UAGUA</styled-content> in 3&#x02032;<styled-content style="fixed-case">UTR</styled-content> of <italic><styled-content style="fixed-case">KRAS</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content>. A, <styled-content style="fixed-case">RNA</styled-content>&#x02010;immunoprecipitation of <styled-content style="fixed-case">MSI</styled-content>2 complexes with anti&#x02010;<styled-content style="fixed-case">MSI</styled-content>2 or control antirabbit IgG antibody, followed by <styled-content style="fixed-case">qRT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content> of <italic><styled-content style="fixed-case">KRAS</styled-content></italic> and <italic><styled-content style="fixed-case">HRAS</styled-content></italic>. Relative enrichment was calculated by enrichment over the control. Western blot analysis as a quality check of immunoprecipitated <styled-content style="fixed-case">MSI</styled-content>2 is also shown. B, Luciferase activities after cotransfection with control or siR&#x02010;<styled-content style="fixed-case">MS</styled-content>i2 and wild&#x02010;type or mutant&#x02010;type <styled-content style="fixed-case">pMIR</styled-content> vectors having the predictive <styled-content style="fixed-case">MSI</styled-content>2 binding site in the 3&#x02032;<styled-content style="fixed-case">UTR</styled-content> of <italic><styled-content style="fixed-case">KRAS</styled-content></italic>. Upper panel shows the position 26&#x02010;42 of the 3&#x02032;<styled-content style="fixed-case">UTR</styled-content> of <italic><styled-content style="fixed-case">KRAS</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content>. Colored sequences indicate the predicted binding site for <styled-content style="fixed-case">MSI</styled-content>2. Site of the mutated sequence is shown in blue. **<italic>P&#x000a0;</italic>&#x0003c;0.01. Means&#x000a0;+&#x000a0;<styled-content style="fixed-case">SD</styled-content> indicated by error bars are shown. NS, not significant. C, Representative surface plasmon resonance (<styled-content style="fixed-case">SPR</styled-content>) sensorgrams for binding of <styled-content style="fixed-case">MSI</styled-content>2 to synthetic <styled-content style="fixed-case">RNA</styled-content>s containing <italic><styled-content style="fixed-case">KRAS</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content> (<styled-content style="fixed-case">UAGUA</styled-content>) or its scrambled sequences (<styled-content style="fixed-case">AAUGU</styled-content>,<styled-content style="fixed-case"> GUUGA</styled-content>, and <styled-content style="fixed-case">AUGAU</styled-content>) (left panel). Dissociation constants between <styled-content style="fixed-case">MSI</styled-content>2 protein and <styled-content style="fixed-case">RNA</styled-content>s shown in the left panel. Average&#x000a0;&#x000b1;&#x000a0;<styled-content style="fixed-case">SD</styled-content> from three experiments (right panel)</p></caption><graphic id="nlm-graphic-11" xlink:href="CAS-110-2189-g005"/></fig><p>In addition, to determine the direct interaction between MSI2 and <italic>KRAS</italic> mRNA, we cloned the predicted MSI2 binding site UAGUA in the 3&#x02032;UTR region of <italic>KRAS</italic> mRNA in a reporter plasmid vector (Figure&#x000a0;<xref rid="cas14035-fig-0005" ref-type="fig">5</xref>B). Results of the luciferase reporter assay indicated that activity of wild&#x02010;type pMIR&#x02010;KRAS was decreased by siR&#x02010;MSI2 compared with that obtained with control siRNA, indicating that the activity paralleled the level of MSI2 protein expression. On the contrary, decrease in the activity of the pMIR vector was almost canceled when the mutated MSI2 binding site AUCAU was used. Thus, these data clearly showed the promoting roles of MSI2 in the translation step of luciferase mRNAs.</p><p>To examine direct interaction between MSI2 and UAGUA, we next used the SPR assay. To this end, a recombinant MSI2 protein containing the two RNA&#x02010;binding domains was expressed (Figure&#x000a0;<xref rid="cas14035-sup-0005" ref-type="supplementary-material">S5</xref>) and immobilized on a sensor&#x02010;chip surface. A synthetic 15&#x02010;mer <italic>KRAS</italic> mRNA containing UAGUA or its scrambled sequence as a control was injected over the sensor chip. As shown in the left panel of Figure&#x000a0;<xref rid="cas14035-fig-0005" ref-type="fig">5</xref>C, the UAGUA sequence gave the highest binding response to the immobilized MSI2 (reaching 50 resonance units at 10&#x000a0;&#x003bc;mol/L). In addition, a dissociation constant (K<sub>d</sub>) of UAGUA for MSI2 was 2&#x02010;5&#x02010;fold lower than that for the control RNA (right panel of Figure&#x000a0;<xref rid="cas14035-fig-0005" ref-type="fig">5</xref>C), suggesting that MSI2 preferentially bound to the UAGUA sequence.</p><p>Collectively, these data showed that MSI2 directly interacted with <italic>KRAS</italic> mRNA by recognizing and binding to one of the specific UAGUA sequences.</p></sec><sec id="cas14035-sec-0012"><label>3.6</label><title>Musashi&#x02010;2 post&#x02010;transcriptionally enhances translation of KRAS</title><p>To investigate how MSI2 regulates the processing of <italic>KRAS</italic> mRNAs after transcription, we first examined the localization of MSI2 in cells by using immunofluorescence. MSI2 was located mainly in the cytoplasm in T24 and 253JB&#x02010;V cells (Figure&#x000a0;<xref rid="cas14035-fig-0006" ref-type="fig">6</xref>A) in agreement with the reports in a public database (The Human Protein Atlas).</p><fig fig-type="Figure" xml:lang="en" id="cas14035-fig-0006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Cell localization of Musashi&#x02010;2 (<styled-content style="fixed-case">MSI</styled-content>2) and functions against <italic><styled-content style="fixed-case">KRAS</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content>. A, Immunofluorescence of <styled-content style="fixed-case">MSI</styled-content>2 (green), a nucleic marker, Hoechst 33342 (blue), and an actin marker, Phalloidin (red) in T24 and 253<styled-content style="fixed-case">JB</styled-content>&#x02010;V cells (left panel). Immunohistochemistry images as obtained from the Human Protein Atlas also show <styled-content style="fixed-case">MSI</styled-content>2 in bladder carcinoma (<styled-content style="fixed-case">BC</styled-content>) tissue (right panel). B, <italic><styled-content style="fixed-case">KRAS</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content> stability curves were plotted as <styled-content style="fixed-case">qRT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content> expression with time. <styled-content style="fixed-case">ANCOVA</styled-content> was used for determining statistical significance. Mean standard error is indicated for each time point. Half&#x02010;life in hours was calculated from the stability curves. NS, not significant. C, Protein expression of translational initiator <styled-content style="fixed-case">eIF</styled-content>4E in <styled-content style="fixed-case">MSI</styled-content>2&#x02010;silenced cells. D, Protein expression levels of <styled-content style="fixed-case">MSI</styled-content>2 and <styled-content style="fixed-case">KRAS</styled-content> in 10 tumor tissue samples from <styled-content style="fixed-case">BC</styled-content> patients. Cases with co&#x02010;upregulated <styled-content style="fixed-case">MSI</styled-content>2 and <styled-content style="fixed-case">KRAS</styled-content> in the tumor samples are highlighted by red boxes. The samples are the same as in Figure&#x000a0;<xref rid="cas14035-fig-0003" ref-type="fig">3</xref>A. N, normal; T, tumor in the same patient. E, Correlation of mRNA expression levels between <italic>MSI2</italic> and <italic>KRAS</italic> in human BC samples from Lee's cohort (n&#x000a0;=&#x000a0;256) estimated by bioinformatics. PCC, Pearson's correlation coefficient</p></caption><graphic id="nlm-graphic-13" xlink:href="CAS-110-2189-g006"/></fig><p>Cellular localization of MSI2 and the findings in the current study suggest that MSI2 might have the ability to regulate the stability or translation of target mRNAs.<xref rid="cas14035-bib-0033" ref-type="ref">33</xref> To determine whether MSI2 could regulate the stability of <italic>KRAS</italic> mRNA, we estimated the rate of mRNA decay after treatment with DRB. Time&#x02010;course RNA decay curves for <italic>KRAS</italic> mRNA were prepared from qRT&#x02010;PCR data after DRB treatment of cells transfected with pF5A&#x02010;control or pF5A&#x02010;MSI2. As a result, the half&#x02010;life of <italic>KRAS</italic> mRNA was not significantly changed in either case, whereas overexpression of MSI2 was achieved in the case of pF5A&#x02010;MSI2 transfection (Figure&#x000a0;<xref rid="cas14035-fig-0006" ref-type="fig">6</xref>B). These data thus showed that MSI2 functioned to enhance the translation of <italic>KRAS</italic> mRNA rather than to stabilize the mRNA, the finding of which is well supported by the results given in Figure&#x000a0;<xref rid="cas14035-fig-0004" ref-type="fig">4</xref>A,B. To further validate that MSI2 regulated the translation, we assessed the expression of translational initiator eIF4E by western blot analysis. Notably, knockdown of <italic>MSI2</italic> induced the downregulation of eIF4E (Figure&#x000a0;<xref rid="cas14035-fig-0006" ref-type="fig">6</xref>C). These data suggested that MSI2 played a role in enhancing translation. Furthermore, western blot analysis showed that MSI2 and KRAS were co&#x02010;upregulated in six cases of 10 clinical BC samples compared with their expression in normal bladder tissues (Figure&#x000a0;<xref rid="cas14035-fig-0006" ref-type="fig">6</xref>D). In Lee's cohort,<xref rid="cas14035-bib-0034" ref-type="ref">34</xref> there was a significant positive correlation of mRNA expression levels between <italic>MSI2</italic> and <italic>KRAS</italic> in human BC (Figure&#x000a0;<xref rid="cas14035-fig-0006" ref-type="fig">6</xref>E). These data suggested that the patients, which had abundant MSI2 mRNA, could have increment of KRAS protein expression through efficient translation by MSI2. Furthermore, we showed that the silencing effect of KRAS by ectopic expression with syn&#x02010;miR&#x02010;143 was certainly canceled by overexpression of MSI2 (Figure&#x000a0;<xref rid="cas14035-sup-0006" ref-type="supplementary-material">S6</xref>). This finding suggested that downregulated expression of MSI2 by miR&#x02010;143 was significant in the growth of BC cells.</p><p>Collectively, these data indicated that MSI2 functioned to accelerate the translation of <italic>KRAS</italic> mRNA in the cytoplasm and had crucial roles as a KRAS enhancer in BC cells. This machinery was closely correlated with KRAS networks, in which there was a positive circuit for enhancement of <italic>KRAS</italic> mRNA expression by KRAS effector signaling (AKT and ERK)<xref rid="cas14035-bib-0010" ref-type="ref">10</xref> (Figures&#x000a0;<xref rid="cas14035-fig-0007" ref-type="fig">7</xref>, <xref rid="cas14035-sup-0007" ref-type="supplementary-material">S7</xref> and <xref rid="cas14035-sup-0008" ref-type="supplementary-material">S8</xref>).</p><fig fig-type="Figure" xml:lang="en" id="cas14035-fig-0007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Schematic diagrams showing the roles of Musashi&#x02010;2 (<styled-content style="fixed-case">MSI</styled-content>2) in <styled-content style="fixed-case">KRAS</styled-content> networks and the association of <styled-content style="fixed-case">MSI</styled-content>2 with <italic><styled-content style="fixed-case">KRAS</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content>. MicroRNA (miR)&#x02010;143/<styled-content style="fixed-case">MSI</styled-content>2/<styled-content style="fixed-case">KRAS</styled-content> cascade (left panel) and possible machinery for <styled-content style="fixed-case">MSI</styled-content>2&#x02010;mediated enhancement of the translation of <italic><styled-content style="fixed-case">KRAS</styled-content></italic>
<styled-content style="fixed-case">mRNA</styled-content> (right panel)</p></caption><graphic id="nlm-graphic-15" xlink:href="CAS-110-2189-g007"/></fig></sec><sec id="cas14035-sec-0013"><label>3.7</label><title>MicroRNA&#x02010;143/MSI2/KRAS cascade on T24 cell&#x02010;xenografted tumors in nude mice</title><p>We have clarified the novel miR&#x02010;143/MSI2/KRAS cascade in&#x000a0;vitro. To further validate the cascade between miR&#x02010;143, MSI2 and KRAS, we examined the antitumor effect by using syn&#x02010;miR&#x02010;143 and siR&#x02010;MSI2 in&#x000a0;vivo. As shown in Figure&#x000a0;<xref rid="cas14035-fig-0008" ref-type="fig">8</xref>A, growth suppression of tumors was observed in the groups treated with siR&#x02010;MSI2 or syn&#x02010;miR&#x02010;143. In addition, the tumor&#x02010;suppressive effect of syn&#x02010;miR&#x02010;143 was greater than that of siR&#x02010;MSI2. Western blot analysis of the tissue samples from grafted tumors showed that MSI2 was significantly silenced in both treated groups, Furthermore, decreased expression of KRAS protein was also shown in both groups as it had been found in&#x000a0;vitro (Figures&#x000a0;<xref rid="cas14035-fig-0002" ref-type="fig">2</xref>B and <xref rid="cas14035-fig-0004" ref-type="fig">4</xref>A), and the KRAS&#x02010;silencing effect of syn&#x02010;miR&#x02010;143 was greater than that of siR&#x02010;MSI2 (Figure&#x000a0;<xref rid="cas14035-fig-0008" ref-type="fig">8</xref>B). These findings suggested that MSI2 contributed to the growth of the engrafted tumor through upregulation of KRAS, and that the miR&#x02010;143/MSI2/KRAS cascade could exist even in an in&#x000a0;vivo experiment.</p><fig fig-type="Figure" xml:lang="en" id="cas14035-fig-0008" orientation="portrait" position="float"><label>Figure 8</label><caption><p>Antitumor activity of siR&#x02010;<styled-content style="fixed-case">MSI</styled-content>2 and syn&#x02010;miR&#x02010;143 in T24 cell&#x02010;xenografted mice. A, Changes in tumor size of mice treated with control si<styled-content style="fixed-case">RNA</styled-content>, siR&#x02010;<styled-content style="fixed-case">MSI</styled-content>2 or syn&#x02010;miR&#x02010;143 (n&#x000a0;=&#x000a0;3; left panel). (Right panel) Representative photograph of tumors. Upper, middle and lower photos show the tumors from control and treated mice, respectively. B, Protein expression levels of <styled-content style="fixed-case">MSI</styled-content>2 and <styled-content style="fixed-case">KRAS</styled-content> in control, siR&#x02010;<styled-content style="fixed-case">MSI</styled-content>2 or syn&#x02010;miR&#x02010;143&#x02010;treated tumor tissues. *<italic>P&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>.05. Means&#x000a0;&#x000b1;&#x000a0;<styled-content style="fixed-case">SD</styled-content> indicated by error bars are shown. miR, microRNA; MSI2, Musashi&#x02010;2</p></caption><graphic id="nlm-graphic-17" xlink:href="CAS-110-2189-g008"/></fig></sec></sec><sec sec-type="discussion" id="cas14035-sec-0014"><label>4</label><title>DISCUSSION</title><p>In the current study, we clarified a novel network operating miR&#x02010;143, MSI2 and KRAS (Figure&#x000a0;<xref rid="cas14035-fig-0007" ref-type="fig">7</xref>). We were also able to show that the expression of KRAS was affected by MSI2 through binding of the latter to <italic>KRAS</italic> mRNA, the finding of which was validated by RNA&#x02010;IP, SPR, and the expression profiles of the genes involved. Previously, we showed that miR&#x02010;143 directly silences KRAS signaling networks;<xref rid="cas14035-bib-0010" ref-type="ref">10</xref>, <xref rid="cas14035-bib-0017" ref-type="ref">17</xref> and Dong et&#x000a0;al<xref rid="cas14035-bib-0030" ref-type="ref">30</xref> reported that miR&#x02010;143 also targets RNA&#x02010;binding protein MSI2. However, the association between these targets of miR&#x02010;143, KRAS and MSI2 had not been previously reported. Given the earlier reports that MSI2 has been suggested to interact preferentially with the UAG&#x02010;containing motifs in the 3&#x02032;UTR region of its target RNAs,<xref rid="cas14035-bib-0021" ref-type="ref">21</xref>, <xref rid="cas14035-bib-0035" ref-type="ref">35</xref>, <xref rid="cas14035-bib-0036" ref-type="ref">36</xref>, <xref rid="cas14035-bib-0037" ref-type="ref">37</xref> we predicted the binding site in <italic>KRAS</italic> mRNA to be UAGUA and showed by a using luciferase reporter assay and the SPR technique (Figure&#x000a0;<xref rid="cas14035-fig-0005" ref-type="fig">5</xref>B,C) that MSI2 protein preferentially binds to the sequence. In addition, it was earlier reported that MSI2 has functions to affect the stabilization or translation of its target mRNAs.<xref rid="cas14035-bib-0021" ref-type="ref">21</xref>, <xref rid="cas14035-bib-0030" ref-type="ref">30</xref>, <xref rid="cas14035-bib-0038" ref-type="ref">38</xref> Based on our results, MSI2 did not impact the stability of <italic>KRAS</italic> mRNA despite its direct binding to it (Figure&#x000a0;<xref rid="cas14035-fig-0006" ref-type="fig">6</xref>B). Given that MSI2 positively regulated the translational initiator eIF4E (Figure&#x000a0;<xref rid="cas14035-fig-0006" ref-type="fig">6</xref>C), we propose that MSI2 functioned to enhance the translation of <italic>KRAS</italic> mRNA rather than its stabilization. With regard to the role of translational regulation, MSI2 is regulated by site&#x02010;specific phosphorylation, which converts MSI2 from a repressor to an activator of target mRNA translation, and MAPK and Ringo/CDK contribute to MSI2 regulatory phosphorylation, as does MSI1.<xref rid="cas14035-bib-0039" ref-type="ref">39</xref>, <xref rid="cas14035-bib-0040" ref-type="ref">40</xref> MAPK also contributes to the translational machinery including eIF4E.<xref rid="cas14035-bib-0041" ref-type="ref">41</xref> MSI2 may be included in the cascades, and MAPK positively regulates eIF4E through phosphorylation of MSI2. In addition, given the RAS signaling pathways, KRAS and HRAS could regulate MSI2 through MAPK indirectly. Indeed, it is reasonable that MSI2 was downregulated in cells by knockdown of <italic>KRAS</italic> and <italic>HRAS</italic>, in which ERK1/2 was also inhibited (Figures&#x000a0;<xref rid="cas14035-fig-0001" ref-type="fig">1</xref>B and <xref rid="cas14035-fig-0004" ref-type="fig">4</xref>C).</p><p>We demonstrated an association between the specific sequence UAGUA and the ability of MSI2 to enhance the translation of its target mRNA. However, the SPR technique showed that the control sequences, despite the absence of a UAG motif, gave a weak binding response to MSI2 protein (Figure&#x000a0;<xref rid="cas14035-fig-0005" ref-type="fig">5</xref>C). These data suggested that the specificity of MSI2 binding to transcripts may not be so high. The impact of MSI2 on its target RNAs could be due not only to binding ability, but also to other mechanisms. The two RNA recognition motif (RRM) of MSI2 are possibly involved in the mechanism. Biochemical and structural studies have suggested that RRM1 contributes the majority of the binding energy and specificity, whereas RRM2 has a more supportive role.<xref rid="cas14035-bib-0037" ref-type="ref">37</xref> In addition, Bennett et&#x000a0;al<xref rid="cas14035-bib-0021" ref-type="ref">21</xref> reported that these two RRM may provide a mechanism for MSI2 to distinguish its veritable targets. However, this machinery is presently barely understood and further validation is warranted.</p><p>In the present study, we clarified that MSI2 directly targeted <italic>KRAS</italic>, promoting translation of its mRNA. The RTK/RAS pathway has been reported to be involved in the regulation of cell proliferation in several cancers.<xref rid="cas14035-bib-0042" ref-type="ref">42</xref>, <xref rid="cas14035-bib-0043" ref-type="ref">43</xref>, <xref rid="cas14035-bib-0044" ref-type="ref">44</xref>, <xref rid="cas14035-bib-0045" ref-type="ref">45</xref> Recent precision medicine studies showed that gene alterations in RTK/RAS pathways occurred in up to 60% of BC patients.<xref rid="cas14035-bib-0046" ref-type="ref">46</xref> Among these signaling pathways, in particular, up to 80% of non&#x02010;muscle invasive BC (NMIBC) harbor activating point mutations in FGFR3,<xref rid="cas14035-bib-0047" ref-type="ref">47</xref>, <xref rid="cas14035-bib-0048" ref-type="ref">48</xref> which activate the RAS/MAPK pathway.<xref rid="cas14035-bib-0004" ref-type="ref">4</xref>, <xref rid="cas14035-bib-0005" ref-type="ref">5</xref>, <xref rid="cas14035-bib-0049" ref-type="ref">49</xref> Moreover, the alteration of <italic>KRAS</italic> occurs more frequently than that of <italic>HRAS</italic>.<xref rid="cas14035-bib-0002" ref-type="ref">2</xref>, <xref rid="cas14035-bib-0003" ref-type="ref">3</xref> Thus, KRAS and KRAS signaling networks are dominant pathways in BC. Previously, we have clarified the signaling networks. The &#x0201c;positive circuit&#x0201d; through the constitutive KRAS activation&#x02010;stimulation of effector signaling pathways (PI3K/AKT and MAPK) occurs in colorectal cancer, resulting in enhanced nuclear KRAS transcription.<xref rid="cas14035-bib-0010" ref-type="ref">10</xref> As shown in Figure&#x000a0;<xref rid="cas14035-sup-0007" ref-type="supplementary-material">S7</xref>, this cascade was also seen in BC cell lines and, again, the &#x0201c;positive circuit&#x0201d; also occurred in HRAS signaling networks. These data suggested that KRAS and HRAS interacted with each other, indicating that either MSI2 or miR&#x02010;143 indirectly affected the expression of HRAS by regulating KRAS. Indeed, inhibition of the signals of ERK and AKT occurred, resulting in indirect regulation of HRAS expression in the case of treatment with siR&#x02010;MSI2 or syn&#x02010;miR&#x02010;143 (Figures&#x000a0;<xref rid="cas14035-fig-0002" ref-type="fig">2</xref>B and <xref rid="cas14035-sup-0008" ref-type="supplementary-material">S8</xref>).</p><p>Recently, it was reported that miR&#x02010;143 has a significant antitumor role in BC. Lin et&#x000a0;al<xref rid="cas14035-bib-0015" ref-type="ref">15</xref> reported that transfection of BC cells with miR&#x02010;143 significantly inhibited cell proliferation through decreased expression of RAS protein. Wang et&#x000a0;al<xref rid="cas14035-bib-0050" ref-type="ref">50</xref> showed that overexpression of miR&#x02010;143 inhibited cell proliferation in BC. Furthermore, we demonstrated previously that syn&#x02010;miR&#x02010;143 functions as a tumor suppressor in BC cells.<xref rid="cas14035-bib-0017" ref-type="ref">17</xref>, <xref rid="cas14035-bib-0032" ref-type="ref">32</xref> In an earlier study, we also showed that miR&#x02010;143 directly targets KRAS signaling networks.<xref rid="cas14035-bib-0010" ref-type="ref">10</xref> Furthermore, it was reported that miR&#x02010;143 also directly targets MSI2 in cervical cancer.<xref rid="cas14035-bib-0030" ref-type="ref">30</xref> In the present study, we clarified the novel association between MSI2 and KRAS, both of which are targets of miR&#x02010;143, validating the interaction between MSI2 and the UAGUA sequence of the <italic>KRAS</italic> transcript in&#x000a0;vitro (Figures&#x000a0;<xref rid="cas14035-fig-0004" ref-type="fig">4</xref> and <xref rid="cas14035-fig-0005" ref-type="fig">5</xref>, <xref rid="cas14035-sup-0006" ref-type="supplementary-material">S6</xref>). Previously, genome&#x02010;wide analyses demonstrated that MSI2 binds to a multitude of target genes.<xref rid="cas14035-bib-0037" ref-type="ref">37</xref> Fox et&#x000a0;al<xref rid="cas14035-bib-0051" ref-type="ref">51</xref> validated targets C&#x02010;MET, BRD4, and HMGA2 in pancreatic cancer, and Park et&#x000a0;al<xref rid="cas14035-bib-0052" ref-type="ref">52</xref> validated 48 genes in hematopoietic stem cells and 11 genes in leukemia stem cells.<xref rid="cas14035-bib-0038" ref-type="ref">38</xref> Thus, as MSI2 binds to a great number of targets, KRAS cannot be listed at the top in genome&#x02010;wide analysis of MSI2&#x02010;ribonucleoproteins. Syn&#x02010;miR&#x02010;143 has allowed us to propose the possibility of association between the two proteins, resulting in a better understanding of the novel miR&#x02010;143/MSI2/KRAS expression system (Figure&#x000a0;<xref rid="cas14035-fig-0007" ref-type="fig">7</xref>).</p><p>Collectively, we showed that miR&#x02010;143 directly impacted MSI2 expression through its RNAi action, which also effectively inhibited KRAS networks as a novel mechanism in human BC. Moreover, this evidence was confirmed by the results of an in&#x000a0;vivo experiment (Figure&#x000a0;<xref rid="cas14035-fig-0008" ref-type="fig">8</xref>). Taken together, these findings indicated the complicated nature of KRAS networks and the tight control of their maintenance.</p></sec><sec id="cas14035-sec-0016"><title>DISCLOSURE</title><p>Authors declare no conflicts of interest for this article.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="cas14035-sup-0001"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-110-2189-s001.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas14035-sup-0002"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-110-2189-s002.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas14035-sup-0003"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-110-2189-s003.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas14035-sup-0004"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-110-2189-s004.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas14035-sup-0005"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-110-2189-s005.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas14035-sup-0006"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-110-2189-s006.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas14035-sup-0007"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-110-2189-s007.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas14035-sup-0008"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-110-2189-s008.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas14035-sup-009"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-110-2189-s009.eps"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas14035-sup-0010"><caption><p>&#x000a0;</p></caption><media xlink:href="CAS-110-2189-s010.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cas14035-sec-0015"><title>ACKNOWLEDGMENTS</title><p>This work was carried out with the support of SHIONOGI. This work was supported by the Project for Cancer Research and Therapeutic Evolution (P&#x02010;CREATE) from Japan Agency for Medical Research and Development (AMED) (16cm0106202&#x000a0;h0001 to YA).</p></ack><ref-list content-type="cited-references" id="cas14035-bibl-0001"><title>REFERENCES</title><ref id="cas14035-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cas14035-cit-0001">
<string-name>
<surname>Siegel</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Jemal</surname>
<given-names>A</given-names>
</string-name>. <article-title>Cancer statistics, 2017</article-title>. <source xml:lang="en">CA Cancer J Clin</source>. <year>2017</year>;<volume>67</volume>:<fpage>7</fpage>&#x02010;<lpage>30</lpage>.<pub-id pub-id-type="pmid">28055103</pub-id></mixed-citation></ref><ref id="cas14035-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cas14035-cit-0002">
<string-name>
<surname>Robertson</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Ahmadie</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Comprehensive molecular characterization of muscle&#x02010;invasive bladder cancer</article-title>. <source xml:lang="en">Cell</source>. <year>2017</year>;<volume>171</volume>:<fpage>540</fpage>&#x02010;<lpage>556</lpage>. e25.<pub-id pub-id-type="pmid">28988769</pub-id></mixed-citation></ref><ref id="cas14035-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cas14035-cit-0003">
<string-name>
<surname>Springer</surname>
<given-names>SU</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Rodriguez Pena</surname>
<given-names>MDC</given-names>
</string-name>, et&#x000a0;al. <article-title>Non&#x02010;invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy</article-title>. <source xml:lang="en">Elife</source>. <year>2018</year>;<volume>7</volume>:<fpage>e32143</fpage>.<pub-id pub-id-type="pmid">29557778</pub-id></mixed-citation></ref><ref id="cas14035-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cas14035-cit-0004">
<string-name>
<surname>Oliveras&#x02010;Ferraros</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cufi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Queralt</surname>
<given-names>B</given-names>
</string-name>, et&#x000a0;al. <article-title>Cross&#x02010;suppression of EGFR ligands amphiregulin and epiregulin and de&#x02010;repression of FGFR3 signalling contribute to cetuximab resistance in wild&#x02010;type KRAS tumour cells</article-title>. <source xml:lang="en">Br J Cancer</source>. <year>2012</year>;<volume>106</volume>:<fpage>1406</fpage>&#x02010;<lpage>1414</lpage>.<pub-id pub-id-type="pmid">22491422</pub-id></mixed-citation></ref><ref id="cas14035-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cas14035-cit-0005">
<string-name>
<surname>Touat</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ileana</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Postel&#x02010;Vinay</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Andre</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Soria</surname>
<given-names>JC</given-names>
</string-name>. <article-title>Targeting FGFR signaling in cancer</article-title>. <source xml:lang="en">Clin Cancer Res</source>. <year>2015</year>;<volume>21</volume>:<fpage>2684</fpage>&#x02010;<lpage>2694</lpage>.<pub-id pub-id-type="pmid">26078430</pub-id></mixed-citation></ref><ref id="cas14035-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cas14035-cit-0006">
<string-name>
<surname>Tsai</surname>
<given-names>FD</given-names>
</string-name>, <string-name>
<surname>Lopes</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>K&#x02010;Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane&#x02010;targeting motif</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source>. <year>2015</year>;<volume>112</volume>:<fpage>779</fpage>&#x02010;<lpage>784</lpage>.<pub-id pub-id-type="pmid">25561545</pub-id></mixed-citation></ref><ref id="cas14035-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cas14035-cit-0007">
<string-name>
<surname>Jinesh</surname>
<given-names>GG</given-names>
</string-name>, <string-name>
<surname>Sambandam</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Vijayaraghavan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Balaji</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mukherjee</surname>
<given-names>S</given-names>
</string-name>. <article-title>Molecular genetics and cellular events of K&#x02010;Ras&#x02010;driven tumorigenesis</article-title>. <source xml:lang="en">Oncogene</source>. <year>2018</year>;<volume>37</volume>:<fpage>839</fpage>&#x02010;<lpage>846</lpage>.<pub-id pub-id-type="pmid">29059163</pub-id></mixed-citation></ref><ref id="cas14035-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cas14035-cit-0008">
<string-name>
<surname>Chen</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Role of miR&#x02010;143 targeting KRAS in colorectal tumorigenesis</article-title>. <source xml:lang="en">Oncogene</source>. <year>2009</year>;<volume>28</volume>:<fpage>1385</fpage>&#x02010;<lpage>1392</lpage>.<pub-id pub-id-type="pmid">19137007</pub-id></mixed-citation></ref><ref id="cas14035-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cas14035-cit-0009">
<string-name>
<surname>Akao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Iio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Naoe</surname>
<given-names>T</given-names>
</string-name>. <article-title>Role of microRNA&#x02010;143 in Fas&#x02010;mediated apoptosis in human T&#x02010;cell leukemia Jurkat cells</article-title>. <source xml:lang="en">Leuk Res</source>. <year>2009</year>;<volume>33</volume>:<fpage>1530</fpage>&#x02010;<lpage>1538</lpage>.<pub-id pub-id-type="pmid">19464056</pub-id></mixed-citation></ref><ref id="cas14035-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cas14035-cit-0010">
<string-name>
<surname>Akao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kumazaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shinohara</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Impairment of K&#x02010;Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR&#x02010;143</article-title>. <source xml:lang="en">Cancer Sci</source>. <year>2018</year>;<volume>109</volume>:<fpage>1455</fpage>&#x02010;<lpage>1467</lpage>.<pub-id pub-id-type="pmid">29498789</pub-id></mixed-citation></ref><ref id="cas14035-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cas14035-cit-0011">
<string-name>
<surname>Akao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Naoe</surname>
<given-names>T</given-names>
</string-name>. <article-title>MicroRNAs 143 and 145 are possible common onco&#x02010;microRNAs in human cancers</article-title>. <source xml:lang="en">Oncol Rep</source>. <year>2006</year>;<volume>16</volume>:<fpage>845</fpage>&#x02010;<lpage>850</lpage>.<pub-id pub-id-type="pmid">16969504</pub-id></mixed-citation></ref><ref id="cas14035-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cas14035-cit-0012">
<string-name>
<surname>Akao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kitade</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kinoshita</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Naoe</surname>
<given-names>T</given-names>
</string-name>. <article-title>Downregulation of microRNAs&#x02010;143 and &#x02010;145 in B&#x02010;cell malignancies</article-title>. <source xml:lang="en">Cancer Sci</source>. <year>2007</year>;<volume>98</volume>:<fpage>1914</fpage>&#x02010;<lpage>1920</lpage>.<pub-id pub-id-type="pmid">17892514</pub-id></mixed-citation></ref><ref id="cas14035-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cas14035-cit-0013">
<string-name>
<surname>Akao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hirata</surname>
<given-names>I</given-names>
</string-name>, et&#x000a0;al. <article-title>Role of anti&#x02010;oncomirs miR&#x02010;143 and &#x02010;145 in human colorectal tumors</article-title>. <source xml:lang="en">Cancer Gene Ther</source>. <year>2010</year>;<volume>17</volume>:<fpage>398</fpage>&#x02010;<lpage>408</lpage>.<pub-id pub-id-type="pmid">20094072</pub-id></mixed-citation></ref><ref id="cas14035-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cas14035-cit-0014">
<string-name>
<surname>Takagi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Iio</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nakagawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Naoe</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tanigawa</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Akao</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Decreased expression of microRNA&#x02010;143 and &#x02010;145 in human gastric cancers</article-title>. <source xml:lang="en">Oncology</source>. <year>2009</year>;<volume>77</volume>:<fpage>12</fpage>&#x02010;<lpage>21</lpage>.<pub-id pub-id-type="pmid">19439999</pub-id></mixed-citation></ref><ref id="cas14035-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cas14035-cit-0015">
<string-name>
<surname>Lin</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>MicroRNA&#x02010;143 as a tumor suppressor for bladder cancer</article-title>. <source xml:lang="en">J Urol</source>. <year>2009</year>;<volume>181</volume>:<fpage>1372</fpage>&#x02010;<lpage>1380</lpage>.<pub-id pub-id-type="pmid">19157460</pub-id></mixed-citation></ref><ref id="cas14035-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cas14035-cit-0016">
<string-name>
<surname>Zhou</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>A panel of eight&#x02010;miRNA signature as a potential biomarker for predicting survival in bladder cancer</article-title>. <source xml:lang="en">J Exp Clin Cancer Res</source>. <year>2015</year>;<volume>34</volume>:<fpage>53</fpage>
<pub-id pub-id-type="pmid">25991007</pub-id></mixed-citation></ref><ref id="cas14035-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cas14035-cit-0017">
<string-name>
<surname>Noguchi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yasui</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Iwasaki</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Replacement treatment with microRNA&#x02010;143 and &#x02010;145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways</article-title>. <source xml:lang="en">Cancer Lett</source>. <year>2013</year>;<volume>328</volume>:<fpage>353</fpage>&#x02010;<lpage>361</lpage>.<pub-id pub-id-type="pmid">23104321</pub-id></mixed-citation></ref><ref id="cas14035-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cas14035-cit-0018">
<string-name>
<surname>Sakakibara</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Satoh</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Okano</surname>
<given-names>H</given-names>
</string-name>. <article-title>Rna&#x02010;binding protein Musashi2: developmentally regulated expression in neural precursor cells and subpopulations of neurons in mammalian CNS</article-title>. <source xml:lang="en">J Neurosci</source>. <year>2001</year>;<volume>21</volume>:<fpage>8091</fpage>&#x02010;<lpage>8107</lpage>.<pub-id pub-id-type="pmid">11588182</pub-id></mixed-citation></ref><ref id="cas14035-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cas14035-cit-0019">
<string-name>
<surname>Wang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yousefi</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Transformation of the intestinal epithelium by the MSI2 RNA&#x02010;binding protein</article-title>. <source xml:lang="en">Nat Commun</source>. <year>2015</year>;<volume>6</volume>:<fpage>6517</fpage>.<pub-id pub-id-type="pmid">25774828</pub-id></mixed-citation></ref><ref id="cas14035-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cas14035-cit-0020">
<string-name>
<surname>Zearfoss</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Deveau</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Clingman</surname>
<given-names>CC</given-names>
</string-name>, et&#x000a0;al. <article-title>A conserved three&#x02010;nucleotide core motif defines Musashi RNA binding specificity</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2014</year>;<volume>289</volume>:<fpage>35530</fpage>&#x02010;<lpage>35541</lpage>.<pub-id pub-id-type="pmid">25368328</pub-id></mixed-citation></ref><ref id="cas14035-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cas14035-cit-0021">
<string-name>
<surname>Bennett</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Riemondy</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Chapnick</surname>
<given-names>DA</given-names>
</string-name>, et&#x000a0;al. <article-title>Genome&#x02010;wide analysis of Musashi&#x02010;2 targets reveals novel functions in governing epithelial cell migration</article-title>. <source xml:lang="en">Nucleic Acids Res</source>. <year>2016</year>;<volume>44</volume>:<fpage>3788</fpage>&#x02010;<lpage>3800</lpage>.<pub-id pub-id-type="pmid">27034466</pub-id></mixed-citation></ref><ref id="cas14035-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cas14035-cit-0022">
<string-name>
<surname>Kanemura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sakakibara</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Musashi1, an evolutionarily conserved neural RNA&#x02010;binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity</article-title>. <source xml:lang="en">Differentiation</source>. <year>2001</year>;<volume>68</volume>:<fpage>141</fpage>&#x02010;<lpage>152</lpage>.<pub-id pub-id-type="pmid">11686236</pub-id></mixed-citation></ref><ref id="cas14035-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cas14035-cit-0023">
<string-name>
<surname>Hemmati</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Nakano</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Lazareff</surname>
<given-names>JA</given-names>
</string-name>, et&#x000a0;al. <article-title>Cancerous stem cells can arise from pediatric brain tumors</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source>. <year>2003</year>;<volume>100</volume>:<fpage>15178</fpage>&#x02010;<lpage>15183</lpage>.<pub-id pub-id-type="pmid">14645703</pub-id></mixed-citation></ref><ref id="cas14035-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cas14035-cit-0024">
<string-name>
<surname>Shu</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>H</given-names>
</string-name>, et&#x000a0;al. <article-title>Expression of the Musashi1 gene encoding the RNA&#x02010;binding protein in human hepatoma cell lines</article-title>. <source xml:lang="en">Biochem Biophys Res Comm</source>. <year>2002</year>;<volume>293</volume>:<fpage>150</fpage>&#x02010;<lpage>154</lpage>.<pub-id pub-id-type="pmid">12054577</pub-id></mixed-citation></ref><ref id="cas14035-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cas14035-cit-0025">
<string-name>
<surname>Barbouti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hoglund</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>
<given-names>B</given-names>
</string-name>, et&#x000a0;al. <article-title>A novel gene, MSI2, encoding a putative RNA&#x02010;binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23)</article-title>. <source xml:lang="en">Can Res</source>. <year>2003</year>;<volume>63</volume>:<fpage>1202</fpage>&#x02010;<lpage>1206</lpage>.</mixed-citation></ref><ref id="cas14035-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cas14035-cit-0026">
<string-name>
<surname>Kharas</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Lengner</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Shahrour</surname>
<given-names>F</given-names>
</string-name>, et&#x000a0;al. <article-title>Musashi&#x02010;2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia</article-title>. <source xml:lang="en">Nat Med</source>. <year>2010</year>;<volume>16</volume>:<fpage>903</fpage>&#x02010;<lpage>908</lpage>.<pub-id pub-id-type="pmid">20616797</pub-id></mixed-citation></ref><ref id="cas14035-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cas14035-cit-0027">
<string-name>
<surname>Kudinov</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Deneka</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nikonova</surname>
<given-names>AS</given-names>
</string-name>, et&#x000a0;al. <article-title>Musashi&#x02010;2 (MSI2) supports TGF&#x02010;beta signaling and inhibits claudins to promote non&#x02010;small cell lung cancer (NSCLC) metastasis</article-title>. <source xml:lang="en">Proc Natl Acad Sci USA</source>. <year>2016</year>;<volume>113</volume>:<fpage>6955</fpage>&#x02010;<lpage>6960</lpage>.<pub-id pub-id-type="pmid">27274057</pub-id></mixed-citation></ref><ref id="cas14035-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cas14035-cit-0028">
<string-name>
<surname>Guo</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Cui</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Quan</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>The novel KLF4/MSI2 signaling pathway regulates growth and metastasis of pancreatic cancer</article-title>. <source xml:lang="en">Clin Cancer Res</source>. <year>2017</year>;<volume>23</volume>:<fpage>687</fpage>&#x02010;<lpage>696</lpage>.<pub-id pub-id-type="pmid">27449499</pub-id></mixed-citation></ref><ref id="cas14035-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cas14035-cit-0029">
<string-name>
<surname>Yang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Musashi&#x02010;2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway</article-title>. <source xml:lang="en">Lab Invest</source>. <year>2016</year>;<volume>96</volume>:<fpage>950</fpage>&#x02010;<lpage>958</lpage>.<pub-id pub-id-type="pmid">27322953</pub-id></mixed-citation></ref><ref id="cas14035-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cas14035-cit-0030">
<string-name>
<surname>Dong</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Xiong</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hanley</surname>
<given-names>SJB</given-names>
</string-name>, <string-name>
<surname>Yue</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Watari</surname>
<given-names>H</given-names>
</string-name>. <article-title>Musashi&#x02010;2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53&#x02010;induced miR&#x02010;143 and miR&#x02010;107 activation</article-title>. <source xml:lang="en">J Exp Clin Cancer Res</source>. <year>2017</year>;<volume>36</volume>:<fpage>150</fpage>.<pub-id pub-id-type="pmid">29073938</pub-id></mixed-citation></ref><ref id="cas14035-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cas14035-cit-0031">
<string-name>
<surname>Chen</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Ezzeddine</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shyu</surname>
<given-names>AB</given-names>
</string-name>. <article-title>Messenger RNA half&#x02010;life measurements in mammalian cells</article-title>. <source xml:lang="en">Methods Enzymol</source>. <year>2008</year>;<volume>448</volume>:<fpage>335</fpage>&#x02010;<lpage>357</lpage>.<pub-id pub-id-type="pmid">19111184</pub-id></mixed-citation></ref><ref id="cas14035-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cas14035-cit-0032">
<string-name>
<surname>Noguchi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hoshino</surname>
<given-names>Y</given-names>
</string-name>, et&#x000a0;al. <article-title>MicroRNA&#x02010;143 functions as a tumor suppressor in human bladder cancer T24 cells</article-title>. <source xml:lang="en">Cancer Lett</source>. <year>2011</year>;<volume>307</volume>:<fpage>211</fpage>&#x02010;<lpage>220</lpage>.<pub-id pub-id-type="pmid">21550168</pub-id></mixed-citation></ref><ref id="cas14035-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cas14035-cit-0033">
<string-name>
<surname>Gerstberger</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hafner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tuschl</surname>
<given-names>T</given-names>
</string-name>. <article-title>A census of human RNA&#x02010;binding proteins</article-title>. <source xml:lang="en">Nat Rev Genet</source>. <year>2014</year>;<volume>15</volume>:<fpage>829</fpage>&#x02010;<lpage>845</lpage>.<pub-id pub-id-type="pmid">25365966</pub-id></mixed-citation></ref><ref id="cas14035-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cas14035-cit-0034">
<string-name>
<surname>Lee</surname>
<given-names>J&#x02010;S</given-names>
</string-name>, <string-name>
<surname>Leem</surname>
<given-names>S&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S&#x02010;Y</given-names>
</string-name>, et&#x000a0;al. <article-title>Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors</article-title>. <source xml:lang="en">J Clin Oncol</source>. <year>2010</year>;<volume>28</volume>:<fpage>2660</fpage>&#x02010;<lpage>2667</lpage>.<pub-id pub-id-type="pmid">20421545</pub-id></mixed-citation></ref><ref id="cas14035-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cas14035-cit-0035">
<string-name>
<surname>Katz</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lambert</surname>
<given-names>NJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Musashi proteins are post&#x02010;transcriptional regulators of the epithelial&#x02010;luminal cell state</article-title>. <source xml:lang="en">eLife</source>. <year>2014</year>;<volume>3</volume>:<fpage>e03915</fpage>.<pub-id pub-id-type="pmid">25380226</pub-id></mixed-citation></ref><ref id="cas14035-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cas14035-cit-0036">
<string-name>
<surname>Lan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Xing</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Douglas</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hanzlik</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>L</given-names>
</string-name>. <article-title>Human oncoprotein Musashi&#x02010;2&#x000a0;N&#x02010;terminal RNA recognition motif backbone assignment and identification of RNA&#x02010;binding pocket</article-title>. <source xml:lang="en">Oncotarget</source>. <year>2017</year>;<volume>8</volume>:<fpage>106587</fpage>&#x02010;<lpage>106597</lpage>.<pub-id pub-id-type="pmid">29290973</pub-id></mixed-citation></ref><ref id="cas14035-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cas14035-cit-0037">
<string-name>
<surname>Kudinov</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Karanicolas</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Golemis</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Boumber</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Musashi RNA&#x02010;binding proteins as cancer drivers and novel therapeutic targets</article-title>. <source xml:lang="en">Clin Cancer Res</source>. <year>2017</year>;<volume>23</volume>:<fpage>2143</fpage>&#x02010;<lpage>2153</lpage>.<pub-id pub-id-type="pmid">28143872</pub-id></mixed-citation></ref><ref id="cas14035-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cas14035-cit-0038">
<string-name>
<surname>Park</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Gonen</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vu</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Musashi2 sustains the mixed&#x02010;lineage leukemia&#x02010;driven stem cell regulatory program</article-title>. <source xml:lang="en">J Clin Invest</source>. <year>2015</year>;<volume>125</volume>:<fpage>1286</fpage>&#x02010;<lpage>1298</lpage>.<pub-id pub-id-type="pmid">25664853</pub-id></mixed-citation></ref><ref id="cas14035-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cas14035-cit-0039">
<string-name>
<surname>Arumugam</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>MacNicol</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, et&#x000a0;al. <article-title>Ringo/cyclin&#x02010;dependent kinase and mitogen&#x02010;activated protein kinase signaling pathways regulate the activity of the cell fate determinant Musashi to promote cell cycle re&#x02010;entry in Xenopus oocytes</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2012</year>;<volume>287</volume>:<fpage>10639</fpage>&#x02010;<lpage>10649</lpage>.<pub-id pub-id-type="pmid">22215682</pub-id></mixed-citation></ref><ref id="cas14035-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cas14035-cit-0040">
<string-name>
<surname>MacNicol</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Cragle</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>McDaniel</surname>
<given-names>FK</given-names>
</string-name>, et&#x000a0;al. <article-title>Evasion of regulatory phosphorylation by an alternatively spliced isoform of Musashi2</article-title>. <source xml:lang="en">Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>11503</fpage>.<pub-id pub-id-type="pmid">28912529</pub-id></mixed-citation></ref><ref id="cas14035-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cas14035-cit-0041">
<string-name>
<surname>Roux</surname>
<given-names>PP</given-names>
</string-name>, <string-name>
<surname>Topisirovic</surname>
<given-names>I</given-names>
</string-name>. <article-title>Signaling pathways involved in the regulation of mRNA translation</article-title>. <source xml:lang="en">Mol Cell Biol</source>. <year>2018</year>;<volume>38</volume>:<fpage>e00070-18</fpage>.<pub-id pub-id-type="pmid">29610153</pub-id></mixed-citation></ref><ref id="cas14035-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cas14035-cit-0042">
<string-name>
<surname>Eser</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schnieke</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Saur</surname>
<given-names>D</given-names>
</string-name>. <article-title>Oncogenic KRAS signalling in pancreatic cancer</article-title>. <source xml:lang="en">Br J Cancer</source>. <year>2014</year>;<volume>111</volume>:<fpage>817</fpage>&#x02010;<lpage>822</lpage>.<pub-id pub-id-type="pmid">24755884</pub-id></mixed-citation></ref><ref id="cas14035-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="cas14035-cit-0043">
<string-name>
<surname>Lemieux</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cagnol</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Beaudry</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Carrier</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rivard</surname>
<given-names>N</given-names>
</string-name>. <article-title>Oncogenic KRAS signalling promotes the Wnt/beta&#x02010;catenin pathway through LRP6 in colorectal cancer</article-title>. <source xml:lang="en">Oncogene</source>. <year>2015</year>;<volume>34</volume>:<fpage>4914</fpage>&#x02010;<lpage>4927</lpage>.<pub-id pub-id-type="pmid">25500543</pub-id></mixed-citation></ref><ref id="cas14035-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="cas14035-cit-0044">
<string-name>
<surname>Wong</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>JB</given-names>
</string-name>, et&#x000a0;al. <article-title>Targeting wild&#x02010;type KRAS&#x02010;amplified gastroesophageal cancer through combined MEK and SHP2 inhibition</article-title>. <source xml:lang="en">Nat Med</source>. <year>2018</year>;<volume>24</volume>:<fpage>968</fpage>&#x02010;<lpage>977</lpage>.<pub-id pub-id-type="pmid">29808010</pub-id></mixed-citation></ref><ref id="cas14035-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="cas14035-cit-0045">
<string-name>
<surname>Regad</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Targeting</surname>
<given-names>RTK</given-names>
</string-name>. <article-title>Signaling pathways in cancer</article-title>. <source xml:lang="en">Cancers</source>. <year>2015</year>;<volume>7</volume>:<fpage>1758</fpage>&#x02010;<lpage>1784</lpage>.<pub-id pub-id-type="pmid">26404379</pub-id></mixed-citation></ref><ref id="cas14035-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="cas14035-cit-0046">
<string-name>
<surname>Sanchez&#x02010;Vega</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Mina</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Armenia</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Oncogenic signaling pathways in the cancer genome Atlas</article-title>. <source xml:lang="en">Cell</source>. <year>2018</year>;<volume>173</volume>:<fpage>321</fpage>&#x02010;<lpage>337</lpage>. e10.<pub-id pub-id-type="pmid">29625050</pub-id></mixed-citation></ref><ref id="cas14035-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="cas14035-cit-0047">
<string-name>
<surname>Knowles</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Hurst</surname>
<given-names>CD</given-names>
</string-name>. <article-title>Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity</article-title>. <source xml:lang="en">Nat Rev Cancer</source>. <year>2015</year>;<volume>15</volume>:<fpage>25</fpage>&#x02010;<lpage>41</lpage>.<pub-id pub-id-type="pmid">25533674</pub-id></mixed-citation></ref><ref id="cas14035-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="cas14035-cit-0048">
<string-name>
<surname>Inamura</surname>
<given-names>K</given-names>
</string-name>. <article-title>Bladder cancer: new insights into its molecular pathology</article-title>. <source xml:lang="en">Cancers</source>. <year>2018</year>;<volume>10</volume>:<fpage>100</fpage>.</mixed-citation></ref><ref id="cas14035-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="cas14035-cit-0049">
<string-name>
<surname>Yadav</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Reactivation of mitogen&#x02010;activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B&#x02010;RAF V600E mutant melanoma</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2012</year>;<volume>287</volume>:<fpage>28087</fpage>&#x02010;<lpage>28098</lpage>.<pub-id pub-id-type="pmid">22730329</pub-id></mixed-citation></ref><ref id="cas14035-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="cas14035-cit-0050">
<string-name>
<surname>Wang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Niu</surname>
<given-names>X</given-names>
</string-name>, et&#x000a0;al. <article-title>miR&#x02010;143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF&#x02010;1R signaling</article-title>. <source xml:lang="en">Oncol Lett</source>. <year>2017</year>;<volume>13</volume>:<fpage>435</fpage>&#x02010;<lpage>440</lpage>.<pub-id pub-id-type="pmid">28123579</pub-id></mixed-citation></ref><ref id="cas14035-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="cas14035-cit-0051">
<string-name>
<surname>Fox</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Lytle</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Jaquish</surname>
<given-names>DV</given-names>
</string-name>, et&#x000a0;al. <article-title>Image&#x02010;based detection and targeting of therapy resistance in pancreatic adenocarcinoma</article-title>. <source xml:lang="en">Nature</source>. <year>2016</year>;<volume>534</volume>:<fpage>407</fpage>&#x02010;<lpage>411</lpage>.<pub-id pub-id-type="pmid">27281208</pub-id></mixed-citation></ref><ref id="cas14035-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="cas14035-cit-0052">
<string-name>
<surname>Park</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Deering</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Y</given-names>
</string-name>, et&#x000a0;al. <article-title>Musashi&#x02010;2 controls cell fate, lineage bias, and TGF&#x02010;beta signaling in HSCs</article-title>. <source xml:lang="en">J Exp Med</source>. <year>2014</year>;<volume>211</volume>:<fpage>71</fpage>&#x02010;<lpage>87</lpage>.<pub-id pub-id-type="pmid">24395885</pub-id></mixed-citation></ref></ref-list></back></article>